26934-35-0

Basic information

• Product Name: 4-[3-(Dimethylamino)propoxy]benzaldehyde
• Synonyms: 4-[3-(DIMETHYLAMINO)PROPOXY]BENZALDEHYDE;4-[3-(Dimethylamino)propoxy]benzaldehyde 96%
• CAS NO: 26934-35-0
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.27
• Product Categories: Aldehydes;C10 to C21;Carbonyl Compounds
• Mol File: 26934-35-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 325.4 °C at 760 mmHg
• Flash Point: >230 °F
• Appearance: /
• Density: 1.031 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00023mmHg at 25°C
• Refractive Index: n20/D 1.543(lit.)
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-[3-(Dimethylamino)propoxy]benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(Dimethylamino)propoxy]benzaldehyde(26934-35-0)
• EPA Substance Registry System: 4-[3-(Dimethylamino)propoxy]benzaldehyde(26934-35-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 26934-35-0(Hazardous Substances Data)

Usage

Uses

4-[3-(Dimethylamino)propoxy]benzaldehyde may be used in chemical synthesis.

InChI:InChI=1/C12H17NO2/c1-13(2)8-3-9-15-12-6-4-11(10-14)5-7-12/h4-7,10H,3,8-9H2,1-2H3

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 109-54-6 3-(Dimethylamino)propyl chloride 
• 82625-25-0 4-(3-chloropropoxy)benzaldehyde 
• 124-40-3 dimethyl amine 
• 3179-63-3 3-Dimethylamino-1-propanol 
• 459-57-4 4-fluorobenzaldehyde 
• 5407-04-5 3-(dimethylamino)propyl chloride hydrochloride 
• 17954-81-3 4-(3-bromopropoxy)benzaldehyde 
• 52413-48-6 3-(N,N'-dimethylamino)propyl methanesulfonate hydrochloride 

Downstream Products

• 65678-27-5 N-[[4-[3-(dimethylamino)propoxy]phenyl]methylene]benezeneethanamine 

Relevant articles and documents

A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity

The synthesis and evaluation of the novel head-to-head bisbenzimidazole compound 2,2-bis-[4′-(3″-dimethylamino-1″-propyloxy)phenyl]-5,5-bi-1 H-benzimidazole is described. An X-ray crystallographic study of a complex with the DNA dodecanucleotide sequence d(CGCGAAT-TCGCG) shows the compound bound in the A/T minor groove region of a B-DNA duplex and that the head-to-head bisbenzimidazole motif hydrogen-bonds to the edges of all four consecutive A:T base pairs. The compound showed potent growth inhibition with a mean IC50 across an ovarian carcinoma cell line panel of 0.31 μM, with no significant cross-resistance in two acquired cisplatin-resistant cell lines and a low level of cross-resistance in the P-glycoprotein overexpressing acquired doxorubicin-resistant cell line. Studies with the hollow fiber assay and in vivo tumor xenografts showed some evidence of antitumor activity.

IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST

Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

Design, Synthesis, and Structure–Activity Relationship Analysis of Thiazolo[3,2-a]pyrimidine Derivatives with Anti-inflammatory Activity in Acute Lung Injury

Acute lung injury (ALI) has a high lethality rate, and interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) contribute most to tissue deterioration in cases of ALI. In this study, we designed and synthesized a new series of thiazolo[3,2-a]pyrimidine derivatives based on a previously identified lead compound, and we evaluated their anti-inflammatory activities. Structure–activity relationship studies led to the discovery of two highly potent inhibitors. The two promising compounds were found to inhibit lipopolysaccharide (LPS)-induced IL-6 and TNF-α release in a dose-dependent manner in mouse primary peritoneal macrophages (MPMs). Furthermore, administration of these compounds resulted in lung histopathological improvements and attenuated LPS-induced ALI in vivo. Taken together, these data indicate that these novel thiazolo[3,2-a]pyrimidine derivatives could be developed as candidate drugs for the treatment of ALI.